Prescription Drug Information: Famotidine

FAMOTIDINE- famotidine tablet, film coated
REMEDYREPACK INC.

1 INDICATIONS AND USAGE

Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of:

  • active duodenal ulcer (DU).
  • active gastric ulcer (GU).
  • symptomatic nonerosive gastroesophageal reflux disease (GERD).
  • erosive esophagitis due to GERD, diagnosed by biopsy.

Famotidine tablets are indicated in adults for the:

  • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).
  • reduction of the risk of duodenal ulcer recurrence.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage

Table 1 shows the recommended dosage of famotidine 20 mg and 40 mg tablets in adult and pediatric patients weighing 40 kg and greater with normal renal function. The use of famotidine 20 mg and 40 mg tablets is not recommended in pediatric patients weighing less than 40 kg because the lowest available strength (20 mg) exceeds the recommended dose for these patients . Use another famotidine formulation for pediatric patients weighing less than 40 kg.

Table 1: Recommended Dosage and Duration of Famotidine Tablets in Adult and Pediatric Patients 40 kg and Greater with Normal Renal Function

Indication

Recommended Dosage

Rec ommended Duration

Active duodenal ulcer (DU)

40 mg once daily; or 20 mg twice daily a

Up to 8 weeks b,c

Active gastric ulcer

40 mg once daily

Up to 8 weeks c

Symptomatic nonerosive GERD

20 mg twice daily

Up to 6 weeks c

Erosive esophagitis diagnosed by endoscopy

20 mg twice daily; or 40 mg twice daily a

Up to 12 weeks

Pathological hypersecretory conditions d

Starting dosage: 20 mg every 6 hours; adjust dosage to individual patient needs Maximum dosage 160 mg every 6 hours

As clinically indicated

Reduction of the risk of DU recurrence d

20 mg once daily

1 year c or as clinically indicated

a Both dosages demonstrated effectiveness in clinical trials [see Clinical Studies ( 14)] .

b In clinical trials, the majority of patients healed within 4 weeks. For patients who do not heal after 4 weeks, consider an additional 2 to 4 weeks of treatment [see Clinical Studies ( 14.1)].

c Longer treatment durations have not been studied in clinical trials [see Clinical Studies ( 14.1, 14.2, 14.3)] .

d In pediatric patients, the safety and effectiveness of famotidine tablets have not been established for the reduction of the risk of duodenal ulcer recurrence or for treatment of pathological hypersecretory conditions [see Use in Specific Populations ( 8.4)] .

2.2 Dosage in Renal Impairment

Dosage adjustments of famotidine tablets are recommended for patients with moderate to severe renal impairment (creatinine clearance less than 60 mL/min) [see Use in Specific Populations ( 8.6)] . Table 2 shows the recommended maximum dosage of famotidine 20 mg or 40 mg tablets for patients with renal impairment, by indication. Use the lowest effective dose. Some dosage adjustments may require switching to other formulations of famotidine (e.g., oral suspension, lower dose tablet).

Table 2: Recommended Maximum Dosage of Famotidine Tablets in Adult and Pediatric Patients 40 kg and Greater with Moderate and Severe Renal Impairment

Indication

Rec o m mended Maximum Dosages

Creatinine clearance 30 to 60 mL/minute

Creatinine clearance less than 30 mL/minute

Active duodenal ulcer (DU)

20 mg once daily; or 40 mg every other day

20 mg every other day a

Active gastric ulcer

20 mg once daily; or 40 mg every other day

20 mg every other day a

Symptomatic nonerosive GERD

20 mg once daily

20 mg every other day a

Erosive esophagitis diagnosed by endoscopy b

20 mg once daily; or 40 mg every other day b

20 mg every other day a,b

40 mg once daily b 20 mg once daily b

Pathological hypersecretory conditions c

Avoid use d

Reduction of the risk of DU recurrence c

20 mg every other day a

(see footnote) e

a An alternate dosage regimen is 10 mg once daily. Since 20 mg or 40 mg tablet strength cannot be used for this dosage regimen, use an alternate famotidine formulation.

b Dosage adjustments for renal impairment are provided for both dosing regimens (20 mg twice daily and 40 mg twice daily) which showed effectiveness for the treatment of erosive esophagitis in clinical trials [see Clinical Studies ( 14.4)] .

c In pediatric patients, the safety and effectiveness of famotidine tablets have not been established for the reduction of the risk of duodenal ulcer recurrence or for treatment of pathological hypersecretory conditions [see Use in Specific Populations ( 8.4)] .

d Doses required to treat pathological hypersecretory conditions may exceed the maximum doses evaluated in patients with impaired renal function. The risk for increased adverse reactions in renally impaired patients treated with famotidine tablets for pathological hypersecretory conditions is unknown.

e Recommended dosage regimen is 10 mg every other day. Since 20 mg or 40 mg tablet strength cannot be used for this dosage regimen, use an alternate famotidine formulation.

2.3 Administration Instructions

  • Take famotidine tablets once daily before bedtime or twice daily in the morning and before bedtime, as recommended.
  • Famotidine tablets may be taken with or without food [see Clinical Pharmacology ( 12.3)] .
  • Famotidine tablets may be given with antacids.

3 DOSAGE FORMS AND STRENGTHS

  • 20 mg tablets: beige, round, unscored, film-coated tablets, debossed with “5728” on one side and “TEVA” on the other side.
  • 40 mg tablets: tan, round, unscored, film-coated tablets, debossed with “5729” on one side and “TEVA” on the other side.

4 CONTRAINDICATIONS

Famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H 2 ) receptor antagonists.

RxDrugLabels.com provides trustworthy package insert and label information about marketed prescription drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by RxDrugLabels.com. Every individual prescription drug label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.

As a leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. RxDrugLabels.com provides the full prescription-only subset of the FDA's repository. Medication information provided here is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2022. All Rights Reserved.